Cardiol Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Thank you for joining us. My name is Edward Nash. I am a Senior Analyst on the Biotech team here at Canaccord Genuity.
It is my pleasure to have with us today the management team of Cardiol Therapeutics. Cardiol is a name that we currently cover with a buy rating. And it's one of the, I think, more interesting names for sure, and have a limited number of names, which makes it even more interesting, I believe, in the cardiology space.
With us, we have David Elsley, who is the President and Chief Executive Officer; and Dr. Andrew Hammer, who is the Chief Medical Officer. And I'll have David give the presentation, and then we'll have perhaps a little bit of time after for any Q&A. With that, I'll turn it over to you, David.
Okay. Thanks, Edward, and good morning, everyone. It's a great pleasure to have the opportunity to present Cardiol Therapeutics. I've had the great pleasure of working in the area of heart medicine
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |